ProCE Banner Activity

CE / CME

HCC in the Setting of Hepatitis B: Key Issues for Clinicians Providing Care for Liver Diseases

Watch this dynamic panel discussion on HCC risk, screening, surveillance, and management, in the setting of patients with hepatitis B.

Pharmacists: 1.25 contact hours (0.125 CEUs)

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: March 26, 2021

Expiration: March 25, 2022

No longer available for credit.

Share

Faculty

Robert S. Brown, Jr.

Robert S. Brown, Jr., MD, MPH

Frank Cardile Professor of Medicine
Chief,
Center for Liver Disease
Columbia University College of Physicians & Surgeons
NewYork-Presbyterian Hospital
New York, New York

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Norah Terrault

Norah Terrault, MD, MPH

Assistant Professor, Medicine and Surgery
Director of Viral Hepatitis Research, Liver Transplantation Program
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Target Audience

This program is intended for physicians, pharmacists, and other healthcare providers caring for patients with or at risk of HCC in the setting of hepatitis B.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify individuals with HBV infection who are at high risk for HCC development
  • Apply guideline-based strategies for HCC screening among appropriate patients with HBV infection
  • Develop interdisciplinary strategies for diagnosing and managing HCC in the setting of hepatitis B

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Robert S. Brown, Jr., MD, MPH

Frank Cardile Professor of Medicine
Chief,
Center for Liver Disease
Columbia University College of Physicians & Surgeons
NewYork-Presbyterian Hospital
New York, New York

Robert S. Brown, Jr., MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb and Gilead Sciences and funds for research support from Gilead Sciences.

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Aligos, Ambys, Dova, Gilead, Mallinckrodt, Shionogi, and Surrozen; funds for research support from Allergan, Arrowhead, Assembly, Bristol-Myers Squibb, Eiger, Gilead, and Janssen; other financial or material support from Generon and Janssen; and has ownership interest in Durect.

Norah Terrault, MD, MPH

Assistant Professor, Medicine and Surgery
Director of Viral Hepatitis Research, Liver Transplantation Program
University of California, San Francisco
San Francisco, California

Norah Terrault, MD, MPH, has disclosed that she has received funds for research support from Gilead, GlaxoSmithKline, and Roche/Genentech.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Jennifer Swanson, MEd

Associate Managing Editor, Hematology/Oncology
Clinical Care Options, LLC

Jennifer Swanson, PharmD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-067-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 26, 2021, through March 25, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve clinicians’ understanding of HCC risk in patients with hepatitis B and their competence in HCC screening, diagnosis, and comanagement with oncologists.